Successful ABO incompatible renal transplantation following rituximab and DFPP after failed immunoadsorption.
Effective antibody removal using PE, DFPP and IA has led to increased access to live donor organs through ABOi RT for patients with chronic kidney disease. However, there have been no head-to-head comparator studies between these modalities, and the choice of technique is usually influenced by cost and institutional preference. We describe the clinical course of a child undergoing ABOi RT, in whom IA without preconditioning with rituximab did not achieve a satisfactory reduction in the antibody titers, who went on to have a successful living donor RT following rituximab and DFPP.
Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester, UK.
Shenal
S
Thalgahagoda
Nicholas J A
NJ
Webb
Denise
D
Roberts
Allison
A
Birch
David V
DV
Milford
Afshin
A
Tavakoli
Mohan
M
Shenoy
D000017:ABO Blood-Group System; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D001787:Blood Group Incompatibility / Q000276:immunology*; D002648:Child; D005260:Female; D005374:Filtration; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007668:Kidney / Q000276:immunology; D007674:Kidney Diseases / Q000276:immunology; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D016030:Kidney Transplantation; D010956:Plasmapheresis / Q000379:methods*; D000069283:Rituximab; D019172:Transplantation Conditioning; D016896:Treatment Outcome
D000017:ABO Blood-Group System; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab
ABOi kidney transplant; double filtration plasmapheresis; immunoadsorption; rituximab